With promising data on its investigational gene therapy for hemophilia A, the 'stage was set' for BioMarin Pharmaceuticals' to debut itself to the bleeding disorders community. But with minimal interaction with patients, caregivers and advocacy groups outside a clinical setting, not to mention in a crowded and competitive setting, BioMarin needed to find a way to engage with the community in a unique and authentic way that reflected the values of the company.
Strategic Insights & Research
In order to understand the unique needs of those living with a bleeding disorder, such as hemophilia, the first step was to find...